API Holdings: Financial & Operational Performance (Q3 FY26 vs Q3 FY25)

27 April 2026

Financial Performance (Q3 FY26 vs Q3 FY25): API Holdings reported a significant improvement in financial performance in Q3 FY26, driven by better cost control and improving unit economics. Revenue growth remained healthy, with the company reporting ~14–15% year-on-year (YoY) growth in 9M FY26, indicating steady demand across its platforms. At the same time, profitability saw a sharp turnaround at the operating level, with EBITDA turning positive (~₹29 crore) compared to a loss of ~₹148 crore in the previous year, marking a major shift from cash burn to cost discipline. However, despite this improvement, profitability at the net level remains under pressure, as Profit Before Tax (PBT) is still negative (~₹351 crore vs ~₹566 crore loss earlier) due to high finance costs and debt burden. This shows that while core operations are improving, overall profitability is still impacted by legacy costs and interest expenses.

Operational Metrics (Q3 FY26 vs Q3 FY25):  Operationally, API Holdings showed clear improvement across all business segments, reflecting tighter cost control and better efficiency. The company operates through three key segments—B2B (distribution), B2C (PharmEasy), and Diagnostics (Thyrocare)—each playing a different role in the business model. The Diagnostics segment continued to be the strongest performer, delivering 20%+ growth and strong profitability, acting as the core profit engine. The B2B segment turned EBITDA positive in Q3 FY26, marking a key milestone after consistent losses, while the B2C segment saw narrowing losses, with EBITDA margins improving significantly due to reduced marketing and delivery costs. At a broader level, operational efficiency improved meaningfully, with working capital days reducing from ~50 to ~40 days, indicating better cash management and faster conversion cycles. Overall, the company has moved from aggressive spending to controlled and efficiency-driven operations.

Strategic Developments & Outlook: API Holdings is undergoing a clear strategic shift from growth-at-all-costs to profitability-focused growth, with strong emphasis on cost control, working capital efficiency, and sustainable margins. The company’s structure is becoming more balanced, where Diagnostics (Thyrocare) drives profits, while B2B stabilizes and B2C gradually improves. Looking ahead, continued improvement in operating efficiency and reduction in finance costs will be key to achieving full profitability. While EBITDA positivity is an important milestone, net profitability will depend on managing debt and interest costs effectively. With improving margins across segments and disciplined execution, API Holdings is positioning itself for a more sustainable and scalable business model in the long term.